Lioudmila Tchistiakova - Andover MA, US Marion T. Kasaian - Charlestown MA, US Debra D. Donaldson - Medford MA, US Xiang-Yang Tan - Reading MA, US Davinder Gill - Burlington MA, US Macy X. Jin - Reading MA, US Bruce Jacobson - Framingham MA, US Samuel J. Goldman - Acton MA, US John Knopf - Carlisle MA, US Angela M. Widom - Acton MA, US
Assignee:
Wyeth - Madison NJ
International Classification:
A61K 39/395 C07K 16/24
US Classification:
4241391, 5303879, 5303873
Abstract:
Agents (e. g. , antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.
Antibodies Against Human Interleukin-13 And Pharmaceutical Compositions Thereof
Marion T. Kasaian - Charlestown MA, US Lioudmila Tchistiakova - Andover MA, US Geertruida M. Veldman - Sudbury MA, US Kimberly Ann Marquette - Somerville MA, US Xiang-Yang Tan - Reading MA, US Debra D. Donaldson - Medford MA, US Laura Long Lin - Weston MA, US Tania Shane - Newton MA, US Amy Sze Pui Tam - Medford MA, US Eric Feyfant - Lexington MA, US Nancy L. Wood - Somerville MA, US Lori J. Fitz - Somerville MA, US Angela M. Widom - Acton MA, US Kevin D. Parris - Auburndale MA, US Samuel J. Goldman - Acton MA, US Jose W. Saldanha - Middlesex, GB
Assignee:
Wyeth - Madison NJ
International Classification:
A61K 39/395
US Classification:
4241331, 4241451, 5303873, 53038823
Abstract:
This application relates to antibodies, e. g. , humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e. g. , a human patient, one or more IL-13-associated disorders, e. g. , respiratory disorders (e. g. , asthma); atopic disorders (e. g. , allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e. g. , atopic dermatitis), and gastrointestinal organs (e. g. , inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.
Lioudmila Tchistiakova - Andover MA, US Marion T. Kasaian - Cambridge MA, US Debra D. Donaldson - Medford MA, US Xiang-Yang Tan - Reading MA, US Davinder Gill - Burlington MA, US Macy X. Jin - Reading MA, US Bruce Jacobson - Framingham MA, US Samuel J. Goldman - Acton MA, US John Knopf - Carlisle MA, US Angela M. Widom - Acton MA, US
Assignee:
Wyeth LLC - Madison NJ
International Classification:
C12N 5/10 C12N 15/13 C12N 15/63
US Classification:
435 696, 4353201, 435325, 536 2353
Abstract:
Agents (e. g. , antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.
Antibodies Against Human Interleukin-13 And Uses Therefor
Marion T. Kasaian - Cambridge MA, US Lioudmila Gennadievna Tchistiakova - Andover MA, US Geertruida Machteld Veldman - Sudbury MA, US Kimberly Ann Marquette - Somerville MA, US Xiang-Yang Tan - Reading MA, US Debra D. Donaldson - Medford MA, US Laura Long Lin - Weston MA, US Tania Shane - Newton MA, US Amy Sze Pui Tam - Medford MA, US Eric Feyfant - Lexington MA, US Nancy L. Wood - Somerville MA, US Lori J. Fitz - Somerville MA, US Angela M. Widom - Acton MA, US Kevin D. Parris - Auburndale MA, US Samuel J. Goldman - Acton MA, US Jose W. Saldanha - Enfield, GB
Assignee:
Wyeth LLC - Madison NJ
International Classification:
A61K 39/395
US Classification:
4241331, 4241581
Abstract:
This application relates to antibodies, e. g. , humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e. g. , a human patient, one or more IL-13-associated disorders, e. g. , respiratory disorders (e. g. , asthma); atopic disorders (e. g. , allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e. g. , atopic dermatitis), and gastrointestinal organs (e. g. , inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.
Methods And Compositions For Modulating Interleukin-21 Receptor Activity
Laura Carter - Medford MA, US Beatriz Carreno - Acton MA, US Leslie Lowe - Sudbury MA, US Matthew Whitters - Hudson MA, US Mary Collins - Natick MA, US Margery Ma - Roxbury MA, US Deborah Young - Melrose MA, US JoAnn Witek - Acton MA, US Glenn Larsen - Sudbury MA, US Marion Kasaian - Charlestown MA, US Debra Donaldson - Medford MA, US Michelle Unger - Chapel Hill NC, US
Assignee:
Wyeth - Madison NJ
International Classification:
A61K039/395 A61K031/525 A61K031/4745 A61K031/415
US Classification:
424/145100, 514/251000, 514/291000, 514/406000
Abstract:
Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.
Il-21 Receptor Knockout Animal And Methods Of Use Thereof
Marion Kasaian - Cambridge MA, US Matthew Whitters - Hudson MA, US Andrea Wurster - Arlington MA, US Mary Collins - Natick MA, US Deborah Young - Melrose MA, US Michael Grusby - Newton MA, US
International Classification:
A01K067/027
US Classification:
800/018000
Abstract:
A transgenic non-human mammal with a disruption in its IL-21 receptor gene is provided, along with methods of using the transgenic non-human mammal.
Divya Chaudhary - Andover MA, US Marion Kasaian - Charlestown MA, US Cara Williams - Methuen MA, US Suzana Marusic - Reading MA, US Robert Czerwinski - North Grafton MA, US
Assignee:
Wyeth - Madison NJ
International Classification:
C12Q001/68 A61K038/00 C12N005/08 C12Q001/48
US Classification:
435015000, 514002000, 435372000
Abstract:
Methods for agents useful for treating asthma are disclosed. The methods include screening for agents that inhibit the production of a PKC-θ protein, as well as for agents that inhibit the kinase activity of a PKC-θ protein, or a functional fragment thereof, wherein such agents are useful for treating asthma. The methods also include screening for agents that inhibit the production of a reporter gene product encoded by a nucleic acid sequence operably linked to a PKC-θ promoter. Also disclosed are methods of treating asthma that include administering an agent that inhibits the production of a functional PKC-θ protein or the kinase activity of a PKC-θ protein or a functional fragment thereof. An isolated mast cell lacking expression of endogenous PKC-θ is also disclosed.
Modulation Of Immunoglobulin Production And Atopic Disorders